Research, Funding and Drug Development

Improvements in outcomes for cancer patients require continued research and innovation.  ACS CAN advocates for robust federal funding for cancer research, as well as research and drug approval policies that accelerate the development of new treatments while still ensuring patient safety.

Research, Funding and Drug Development Resources:

By focusing explicitly on bold, transformative, and applied research projects, ARPA-H holds the potential to quickly bridge the gap between the research lab and the patient. 

To ensure that the research being supported today yields the cancer treatments of tomorrow, Congress must sustain and expand the support it is currently providing.

ACS CAN was joined by 22 other organizations in proposing the HHS Office of Inspector General (OIG) adopt a new regulatory safe harbor from the Anti-kickback Statute (AKS) that would allow clinical trial sponsors to financially support patients to offset extra non-medical costs associated with cl

Pharmacogenomic (PGx) testing is a component of precision medicine that involves examining a patient’s inherited genes to detect variations that may impact the way a drug is broken down, absorbed and used within the body. 

As part of his renewed Cancer Moonshot initiative, President Biden has set the goal of reducing cancer deaths by 50% by 2050. ACS and ACS CAN are committed to helping achieve that goal by tackling cancer at every angle.

ACS CAN submitted comments to the U.S. Food and Drug Administration (FDA) on the Diversity Plans To Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials Draft Guidance for Industry. 

The user fee program has provided critical resources for FDA to review drug and device applications, as well as to develop regulatory science and policy.

In response to the Biden Administration's request for information regarding actions being taken toward the achievement the Cancer Moonshot goals, ACS and ACS CAN submitted a list of major initiatives and activites the organizations are pursuing. 

ACS CAN submitted comments to the U.S. Food and Drug Administration (FDA) Draft Guidance on Digital Health Technologies for Remote Data Acquisition in Clinical Investigations.